MILESTONE PHARMACEUTICALS IN (MIST) Stock Fundamental Analysis

NASDAQ:MIST • CA59935V1076

1.69 USD
-0.01 (-0.59%)
At close: Feb 23, 2026
1.69 USD
0 (0%)
Pre-Market: 2/24/2026, 5:54:28 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MIST. MIST was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MIST have multiple concerns. MIST does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year MIST has reported negative net income.
  • In the past year MIST has reported a negative cash flow from operations.
  • MIST had negative earnings in each of the past 5 years.
  • MIST had a negative operating cash flow in each of the past 5 years.
MIST Yearly Net Income VS EBIT VS OCF VS FCFMIST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • MIST has a Return On Assets of -66.11%. This is in the lower half of the industry: MIST underperforms 68.75% of its industry peers.
  • MIST's Return On Equity of -282.97% is on the low side compared to the rest of the industry. MIST is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
ROA -66.11%
ROE -282.97%
ROIC N/A
ROA(3y)-70.9%
ROA(5y)-56.36%
ROE(3y)-253.25%
ROE(5y)-166.55%
ROIC(3y)N/A
ROIC(5y)N/A
MIST Yearly ROA, ROE, ROICMIST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • MIST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIST Yearly Profit, Operating, Gross MarginsMIST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • MIST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MIST has been increased compared to 1 year ago.
  • The number of shares outstanding for MIST has been increased compared to 5 years ago.
  • The debt/assets ratio for MIST is higher compared to a year ago.
MIST Yearly Shares OutstandingMIST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
MIST Yearly Total Debt VS Total AssetsMIST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -5.53, we must say that MIST is in the distress zone and has some risk of bankruptcy.
  • MIST's Altman-Z score of -5.53 is on the low side compared to the rest of the industry. MIST is outperformed by 64.06% of its industry peers.
  • A Debt/Equity ratio of 2.74 is on the high side and indicates that MIST has dependencies on debt financing.
  • MIST has a worse Debt to Equity ratio (2.74) than 80.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.74
Debt/FCF N/A
Altman-Z -5.53
ROIC/WACCN/A
WACC8.52%
MIST Yearly LT Debt VS Equity VS FCFMIST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • MIST has a Current Ratio of 8.24. This indicates that MIST is financially healthy and has no problem in meeting its short term obligations.
  • MIST has a Current ratio of 8.24. This is in the better half of the industry: MIST outperforms 73.96% of its industry peers.
  • MIST has a Quick Ratio of 8.24. This indicates that MIST is financially healthy and has no problem in meeting its short term obligations.
  • MIST has a Quick ratio of 8.24. This is in the better half of the industry: MIST outperforms 74.48% of its industry peers.
Industry RankSector Rank
Current Ratio 8.24
Quick Ratio 8.24
MIST Yearly Current Assets VS Current LiabilitesMIST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for MIST have decreased by -2.35% in the last year.
  • The Revenue for MIST has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-2.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MIST will show a very strong growth in Earnings Per Share. The EPS will grow by 22.73% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6%
EPS Next 2Y11.31%
EPS Next 3Y-6.13%
EPS Next 5Y22.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIST Yearly Revenue VS EstimatesMIST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MIST Yearly EPS VS EstimatesMIST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MIST. In the last year negative earnings were reported.
  • Also next year MIST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIST Price Earnings VS Forward Price EarningsMIST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIST Per share dataMIST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • MIST's earnings are expected to decrease with -6.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.31%
EPS Next 3Y-6.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MIST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (2/23/2026, 8:01:01 PM)

Premarket: 1.69 0 (0%)

1.69

-0.01 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-11
Inst Owners45.72%
Inst Owner Change-21.68%
Ins Owners3.57%
Ins Owner Change-0.05%
Market Cap143.94M
Revenue(TTM)N/A
Net Income(TTM)-58.01M
Analysts80
Price Target6.73 (298.22%)
Short Float %12.21%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.9%
Min EPS beat(2)-10.47%
Max EPS beat(2)28.26%
EPS beat(4)1
Avg EPS beat(4)-18.6%
Min EPS beat(4)-64.28%
Max EPS beat(4)28.26%
EPS beat(8)4
Avg EPS beat(8)-1.28%
EPS beat(12)8
Avg EPS beat(12)2.42%
EPS beat(16)10
Avg EPS beat(16)3.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.11%
EPS NY rev (1m)0%
EPS NY rev (3m)12.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.02
P/tB 7.02
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.11%
ROE -282.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.9%
ROA(5y)-56.36%
ROE(3y)-253.25%
ROE(5y)-166.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.24
Quick Ratio 8.24
Altman-Z -5.53
F-Score3
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)151.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-6%
EPS Next 2Y11.31%
EPS Next 3Y-6.13%
EPS Next 5Y22.73%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.27%
EBIT Next 3Y-12.79%
EBIT Next 5Y29.19%
FCF growth 1Y13.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.89%
OCF growth 3YN/A
OCF growth 5YN/A

MILESTONE PHARMACEUTICALS IN / MIST FAQ

What is the ChartMill fundamental rating of MILESTONE PHARMACEUTICALS IN (MIST) stock?

ChartMill assigns a fundamental rating of 1 / 10 to MIST.


Can you provide the valuation status for MILESTONE PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 0 / 10 to MILESTONE PHARMACEUTICALS IN (MIST). This can be considered as Overvalued.


What is the profitability of MIST stock?

MILESTONE PHARMACEUTICALS IN (MIST) has a profitability rating of 0 / 10.


What is the financial health of MILESTONE PHARMACEUTICALS IN (MIST) stock?

The financial health rating of MILESTONE PHARMACEUTICALS IN (MIST) is 3 / 10.